Calidi Biotherapeutics Presents Preclinical Cancer Data
The company showcased two novel platforms designed to improve tumor eradication during the ESMO Congress in Madrid.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Do you believe new targeted cancer therapies currently in development will eventually improve survival rates?
Calidi Biotherapeutics unveiled new preclinical data for its RedTail and In Situ TCE platforms at the 2026 European Society for Medical Oncology Congress. These experimental systems aim to enhance the delivery and activation of targeted cancer therapies.
Why it matters
The In Situ TCE platform is designed to overcome significant clinical barriers such as systemic toxicity and the immunosuppressive environment surrounding tumors. By turning tumors into biofactories, this approach aims to improve the effectiveness of T-cell engagers.
The CLD-401 candidate demonstrated complete tumor eradication in 80% of treated mice, while the In Situ TCE platform generated approximately 10 ng/mL of tumor-targeted TCE in study models.
The players
Calidi Biotherapeutics
This clinical-stage company specializes in the development of proprietary cell-based and oncolytic virus platforms for cancer immunotherapy.
European Society for Medical Oncology
This is a professional organization dedicated to the study and treatment of cancer that hosts global congresses for the presentation of new research.
The details
The RedTail platform utilizes an engineered enveloped oncolytic virus to shield therapeutic payloads from immune clearance during delivery. Meanwhile, the In Situ TCE platform uses the TROP-2-targeted candidate CLD-501 and the EpCAM-targeted candidate CLD-502 to activate T-cells directly within the tumor site.
Timeline
The data presentations occurred on October 24, 2026.
The ESMO Congress 2026 was held in Madrid during the week prior to October 27, 2026.
Health Landscape
The findings presented at the ESMO Congress 2026 mark an evolution in how oncolytic viruses are engineered to bypass immune clearance. This research reflects a broader trend of leveraging local tumor microenvironments to manufacture therapies in situ rather than relying solely on systemic delivery.
These preclinical advancements may eventually lead to new treatment options for patients with metastatic non-small cell lung cancer and head and neck cancer. However, as the research is in the early stages, it does not currently impact clinical practice or patient access to care.
The takeaway
These findings highlight a significant shift toward using the tumor environment itself as a production site for immune-activating drugs. Ongoing efforts by the developer to secure strategic partnerships will be the primary driver of moving these technologies into clinical testing phases.
Further reading
Learn more about the latest advancements in the field of oncology research in our Cancer section.
Live Poll
Do you believe new targeted cancer therapies currently in development will eventually improve survival rates?
